Ligand id: 5004

Name: infliximab

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: infliximab

View interactive charts of activity data from ChEMBL and GtoPdb across species (New!)

Bioactivity Comments
Infliximab has been reported to induce an anti-chimeric antibody response in almost 15% of Crohns cisease patients (47 tested) [5]. This indicates that as predicited, humans can mount an immune response to whole murine variable domains, and is the underlying rationale promoting the development of clinical antibodies with variable domains with more human character (i.e. humanised or fully human monoclonal developments).
Selectivity at human ligand targets
Key to terms and symbols Click column headers to sort
Target Type Action Affinity Units Concentration range (M) Reference
tumour necrosis factor shed form Antibody Binding 8.7 pKd - 4
pKd 8.7 (Kd 1.8x10-9 M) [4]
Description: Binding affinity of antibody cA2 to recombinant human TNFα